Search Results
Your search for The ,The matches 35552 pages
Showing 11901 - 11950Next-Generation BRAF Inhibitor Shows Activity in Phase I/II Trial
A new drug designed to treat cancers in patients with an altered BRAF gene showed activity and had a favorable safety profile in an early-phase trial. These findings were presented by Janku et al at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (Abstract LBA-05)....
Radiotherapy With Cisplatin vs Cetuximab in Previously Untreated Patients With Locoregionally Advanced Head and Neck Cancer
In the Swedish ARTSCAN III trial reported in the Journal of Clinical Oncology, Gebre-Medhin et al found that radiotherapy with concomitant cetuximab did not improve outcomes vs radiotherapy with cisplatin in patients with previously untreated, locoregionally advanced head and neck squamous cell...
USPSTF Issues Draft Recommendation on Screening for Colorectal Cancer
On October 27, the U.S. Preventive Services Task Force (USPSTF) posted a draft recommendation statement on screening for colorectal cancer. For the first time, the Task Force is recommending that screening start at age 45. This is a B recommendation, meaning the USPSTF recommends the service; that...
Youssef Zeidan, MD, PhD, on HER2-Positive Breast Cancer: Deintensifying Radiation Therapy
Youssef Zeidan, MD, PhD, of the American University of Beirut Medical Center, discusses study findings showing that breast-conserving surgery, whole-breast irradiation, and trastuzumab offer effective local tumor control for patients with HER2-positive breast cancer. An additional radiation boost...
Paul Sargos, MD, on Prostate Cancer: Adjuvant or Early Salvage Radiotherapy Plus Androgen Deprivation
Paul Sargos, MD, of the Institut Bergonié, discusses phase III findings from the GETUG-AFU 17 study, which compared adjuvant vs early salvage radiotherapy, both combined with short-term androgen-deprivation therapy after radical prostatectomy for localized prostate cancer. Although lacking...
Juliane Hörner-Rieber, MD, on Breast Cancer: Boosting Intensity-Modulated and Conventional Radiotherapies
Juliane Hörner-Rieber, MD, of Heidelberg University Hospital, discusses phase III results of the MINT trial, which showed that conventionally fractionated intensity-modulated radiotherapy with a simultaneous integrated boost was noninferior to three-dimensional conformal radiotherapy followed by a...
Arjun Sahgal, MD, on Reducing the Pain of Spinal Metastases: SBRT vs Palliative Radiotherapy
Arjun Sahgal, MD, of the Sunnybrook Health Sciences Centre, discusses results of the first phase III trial to suggest that dose escalation with stereotactic body radiotherapy may be superior to conventional palliative radiotherapy in improving pain outcomes for patients with spinal bone metastases...
Neha Vapiwala, MD, on Prostate Cancer: Imaging and the Decision to Treat With Radiation
Neha Vapiwala, MD, of the University of Pennsylvania, who served as a discussant for LBA1, summarizes her review of this study of patients with prostate cancer who had biochemical recurrence in the post-prostatectomy setting, who were candidates for salvage radiotherapy, and who received either...
FDA Approves Companion Diagnostic for Three Targeted Therapies for Advanced Ovarian, Breast, and Non–Small Cell Lung Cancers
On October 27, the U.S. Food and Drug Administration (FDA) approved the FoundationOne Liquid CDx test for three new companion diagnostic indications to help match patients who may benefit from treatment with specific FDA-approved targeted therapies. The new indications are for alpelisib (Piqray) in ...
Trends and Outcomes Among Hispanic Women of Different Races With Breast Cancer
In a National Cancer Database analysis reported in JCO Oncology Practice, Champion et al identified patterns in disease characteristics, time to surgery, and overall survival among Hispanic patients of different races and among Hispanic and non-Hispanic women of the same race. Study Details The...
Stereotactic Radiosurgery May Delay Cognitive Deterioration vs WBRT in Patients With Numerous Brain Metastases
Stereotactic radiosurgery (SRS) may represent a new standard of care for patients with four or more brain metastases, replacing whole-brain radiation therapy (WBRT) in this setting, according to a phase III study presented at the virtual 2020 American Society for Radiation Oncology (ASTRO) Annual...
Fluciclovine PET Imaging vs Conventional Imaging in Prostate Cancer
The addition of the radiotracer fluciclovine to positron-emission tomography (PET) imaging for treatment planning led to superior failure-free survival compared with conventional imaging in men with prostate cancer who had undergone radical prostatectomy and were experiencing biologic recurrence of ...
Targeted Inhibitor of Mutant KRAS Gene Shows Activity in Early Trial
Adagrasib (MRTX849), a novel agent that targets a mutated form of the KRAS gene—the most commonly altered oncogene in human cancers, and one long considered “undruggable”—caused tumor shrinkage in most patients in a clinical trial, with manageable side effects, researchers reported at the 32nd...
Companion Diagnostic to Identify NTRK Fusions in Patients With Solid Tumors Eligible for Treatment With Larotrectinib Approved by the FDA
On October 23, the U.S. Food and Drug Administration (FDA) approved the next-generation sequencing–based FoundationOne CDx test as a companion diagnostic to identify fusions in the neurotrophic receptor tyrosine kinase (NTRK) genes NTRK1, NTRK2, and NTRK3 in DNA isolated from tumor tissue specimens ...
Survey Shows Many Patients With Cancer Willing to Take Part in Clinical Trials Despite Coronavirus
Patient Power, a patient-driven cancer news organization, reported that a majority of patients with cancer still want to participate in clinical trials despite the COVID-19 pandemic, according to a recent survey of 1,485 patients. The Patient Power COVID-19 Cancer Trial Survey, the second Patient...
SHP2 Inhibition May Counter Resistance Mechanisms in Lung Cancer
Recent preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, an affiliate of Navire Pharma, found that the novel SHP2 inhibitor IACS-13909 may be able to overcome therapeutic resistance mechanisms in non–small cell lung cancer (NSCLC). The data, which...
Becoming Acquainted With Cancer
Editor’s Note: The ASCO Post learned of the death of Patrick Beauregard due to colorectal cancer on September 6, 2020. Just weeks after my wedding in late summer of 2017, I had a sudden bout of abdominal pain so severe that it sent me to the emergency room. I was just 29 years old and in great...
Remembering Patrick H. Beauregard: ‘Selfless in His Efforts to Raise Awareness’ of Colorectal Cancer in Young Adults
The editors of The ASCO Post are sad to report the death of Patrick H. Beauregard on September 6, 2020. The cause was colorectal cancer. Diagnosed with stage IV disease in 2017 at the age of 29, Mr. Beauregard dedicated the last 3 years of his life to raising awareness of colorectal cancer in...
Early-Career ASCO Member and Breast Medical Oncologist, Tomas Lyons, MB BCh, BAO, MRCPI, Dies at 38
Tomas Lyons, MB BCh, BAO, MRCPI, a medical oncologist at the Evelyn H. Lauder Breast Center Memorial Sloan Kettering Cancer Center in New York, died suddenly on September 29 at the age of 38. During his career at Memorial Sloan Kettering (MSK), he was a celebrated collaborator on multidisciplinary ...
Joan H. Marks, Pioneer in Genetic Counseling, Dies at 91
Joan H. (Rosen) Marks, a pioneer in genetic counseling, died on September 14, 2020. She was 91. Ms. Marks received an honorary Doctor of Science degree from Sarah Lawrence College in Bronxville, New York, in 2019, in recognition of her contributions and leadership to the College and to society, the ...
Continued Benefit of First-Line Nivolumab vs Dacarbazine in Advanced BRAF Wild-Type Melanoma
The 5-year outcomes of the CheckMate 066 trial, reported in the Journal of Clinical Oncology by Caroline Robert, MD, PhD, of Gustave Roussy, Villejuif, France,and colleagues, show continued benefit of first-line nivolumab vs dacarbazine in advanced BRAF wild-type melanoma and support evidence that ...
Did You Know ASCO Has Resources on COVID-19 for People With Cancer?
ASCO’s award-winning Cancer.Net blog has been providing updated content and resources on COVID-19 for people with cancer since the pandemic started. Send your patients to www.cancer.net/blog for trusted COVID-19 information, financial resources, and more. All content is available in multiple...
Your Stories: ‘The Family Business’
International business leader Riccardo Braglia has experienced great losses due to cancer. In “The Family Business,” he shares with ASCO Chief Executive Officer Clifford A. Hudis, MD, FACP, FASCO, how the perspective he gained inspires what he gives to help patients everywhere. “My grandmother, my ...
Expect Questions About Increased Cancer Mortality Risk Among Patients Diagnosed With DCIS
A large cohort study1 finding that the risk of dying of breast cancer was increased threefold after a DCIS diagnosis may cause patients diagnosed with DCIS to ask what they can do to reduce that risk. Currently, there is little that most patients can do. “The lifetime risk of death following DCIS...
Breaking Social Barriers to Conquer Cancer
Kala Visvanathan, MD, MHS, is working to prevent cancer in every patient. With the help of donor-supported grants, including a Career Development Award from Conquer Cancer®, the ASCO Foundation, Dr. Visvanathan researches cancer prevention and strategies to prevent cancer recurrence. “To be...
Focus on Preventing Invasive Recurrence in Women With DCIS Does Not Sufficiently Address Breast Cancer Mortality
A study published recently by Giannakeas et al looked at the risk of death from breast cancer for women diagnosed with ductal carcinoma in situ (DCIS).1 The investigators anticipated that treatment would eliminate the risk of invasive ipsilateral recurrence and prevent subsequent mortality from...
Impactful 2020 Virtual Advocacy Summit: New Environment, Same Goals
The Association for Clinical Oncology (ASCO) held its first-ever virtual Advocacy Summit and online Week of Action September 9–18, 2020. The largest Advocacy Summit to date, 170 ASCO volunteer leaders and oncology care providers participated in 200 virtual meetings with members of Congress and...
Emily Whitehead, Early Recipient of CAR T-Cell Therapy for ALL, Celebrates 8 Years Cancer-Free
Among the success stories in the treatment of acute lymphoblastic leukemia (ALL) in children and young adults is the development of chimeric antigen receptor (CAR) T-cell therapy. The field of cellular immunotherapy was still in its infancy in 2012 when Emily Whitehead, then 7, became the first...
Personal Testimonial: CAR-modified T Cells in Adults
Twelve adults with chronic lymphocytic leukemia (CLL) have been treated with CD19-targeted chimeric antigen receptor (CAR) T-cell therapy at the University of Pennsylvania in Philadelphia by Carl June, MD, Richard W. Vague Professor in Immunotherapy, and colleagues. These were all end-stage...
Preliminary Progress with Genetically Engineered T Cells in Treating Childhood ALL
Two small phase I studies at separate centers demonstrated encouraging results in the treatment of children with acute lymphoblastic leukemia (ALL) using reinfused autologous genetically engineered T cells. Results of both studies were presented at the Annual Meeting of the American Association for ...
New ASCO-SEP Edition Available: Expands Reach to Global Oncology Community
The seventh edition of the ASCO Self-Evaluation Program® (ASCO-SEP®) is now available online, expanding its reach to physicians and advanced practitioners. The latest edition features new content that addresses oncologic care in a global setting. The new edition of ASCO-SEP includes 22 chapters of...
Bloodletting by a Phleam
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Anesthesia Era 1845–1875 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. Photograph courtesy of Stanley B. Burns, MD, and The Burns Archive. For ...
UICC Welcomes New President, President-Elect, and Board of Directors for 2020–2022
At the recent General Assembly of the Union for International Cancer Control (UICC), which was held virtually for the first time, Anil D’Cruz, MD, of India, was welcomed as the organization’s new President. Full member organizations also elected the 2020–2022 Board of Directors, including...
Recurrence-Free Survival Benefit Maintained With Adjuvant Nivolumab vs Ipilimumab in Stage IIIB–IIIC and IV Melanoma
As reported in The Lancet Oncology by Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, and colleagues, 4-year results of the CheckMate 238 trial show continued benefit of adjuvant nivolumab vs ipilimumab in recurrence-free survival and metastasis-free...
Breast Cancer and Radiation Researcher David Gius, MD, PhD, Joins Mays Cancer Center
David Gius, MD, PhD, a breast cancer and radiation researcher, has joined the Mays Cancer Center, home to The University of Texas Health San Antonio MD Anderson. He was recruited to the Mays Cancer Center from the Robert H. Lurie Comprehensive Cancer Center at Northwestern University with a $6...
The Secret History of Cancer Chemotherapy
“The summons came in the middle of the night. He was awake at the first harsh jangle of the telephone…. Always a light sleeper, Lieutenant Colonel Stewart Francis Alexander attributed the trait to his father, an old-fashioned family practitioner whose response to every late-night distress call was...
A Gritty Journey Into a Rare Cancer and Back
Over the past decade, a prolific number of cancer memoirs have been published, and some have been award-winning bestsellers. When entering a crowded genre, it is best to have something that sets your story apart. Judith Dwyer Fugate did just that with a memoir about a rare tumor that has rarely if...
Cleveland Clinic Announces Oncology Staff Appointments
Cleveland Clinic recently announced the following additions to its oncology staff: Ruth Keri, PhD, has joined Cleveland Clinic Lerner Research Institute Department of Cancer Biology. She will study breast cancer, focusing on identifying the molecular processes that control the formation of breast...
UCLA Researchers’ Efforts in Melanoma Receive $13M Boost From NIH
University of California, Los Angeles (UCLA) researchers have received a $13 million grant from the National Institutes of Health (NIH) to find new ways to overcome melanoma resistance to some of the most promising targeted therapies and immunotherapies. There have been significant advancements in...
The Gut, Our Choices, and Gynecologic Cancers: Investigating an Unlikely Trio
Disturbance of the gut microbial metabolism is thought to be the root cause of human diseases. Bacteria, viruses, and fungi affect their human hosts in numerous ways. There is evidence to support the theory that microbes, through their genetic makeup, gene products, and metabolites, play a role in...
Expert Point of View: Bartosz Chmielowski, MD, PhD
The invited discussant of LEAP-004, Bartosz Chmielowski, MD, PhD, Associate Clinical Professor at the University of California Los Angeles Jonsson Comprehensive Cancer Center, commented: “The response rate of 21% was quite impressive for this patient population. Patients previously treated with an...
Advanced Melanoma: Lenvatinib Plus Pembrolizumab After Disease Progression on Anti–PD-1 Therapy
Checkpoint inhibitors can be lifesaving for many patients with advanced melanoma, but those who experience disease progression currently have few treatment options. The combination of a tyrosine kinase inhibitor and an anti–PD-1 agent may offer some hope in this setting, according to a study of...
Pay-for-Performance Program to Reimburse Oncology Practices for Prescribing Evidence-Based Cancer Drugs
A pay-for-performance program that offers enhanced reimbursement to oncology practices for prescribing high-quality, evidence-based cancer drugs increased use of these drugs without significantly changing total spending on care, Penn Medicine researchers reported in a study published in the Journal ...
Expert Point of View: Salah-Eddin Al-Batran, MD
Salah-Eddin Al-Batran, MD, Director of the Institute of Clinical Cancer Research and Director of GI Oncology at Krankenhaus Nordwest-University Cancer Center, Frankfurt, Germany, commented on KEYNOTE-590 at a press briefing. Dr. Al-Batran noted that the prognosis for advanced esophageal cancer is...
Dana-Farber/Harvard Cancer Center Wins Federal Grant to Accelerate Ovarian Cancer Research
Dana-Farber/Harvard Cancer Center (DF/HCC) has been awarded a $12 million grant from the National Cancer Institute (NCI) to bring promising ovarian cancer research from the laboratory to clinical practice. The highly competitive Specialized Programs of Research Excellence (SPORE) grant will help...
First-Line Pembrolizumab Plus Chemotherapy Improves Survival in Esophageal Cancer
As first-line therapy for advanced esophageal cancer, pembrolizumab added to chemotherapy improved overall survival in the KEYNOTE-590 population. Not only did patients with high PD-L1 expression benefit, the value of checkpoint inhibition was observed for the whole population, the trial’s...
Panel With Diverse Perspectives Explores Strategies to Reduce Costs for Cancer Care
“Imagine that it’s 5 years from now, and we are in a situation where the cost of cancer care has flattened, and costs are even going down,” said Clifford Goodman, PhD, a Senior Vice President at the Lewin Group, turning to a panel of oncology and policy experts at his side. “What policies got us...
Isabelle Tabah-Fisch, MD, Drug Researcher, Industry Executive, Dies at 64
Isabelle Tabah-Fisch, MD, a medical oncologist in Paris who contributed greatly to drug development, died August 28, 2020, at age 64. An announcement about Dr. Tabah-Fisch’s death was made by GamaMabs, where she served as Chief Medical Officer until her retirement in March 2020. Under her...
Susan G. Komen to Present 2020 Brinker Awards for Scientific Distinction
Susan G. Komen is recognizing two widely respected and innovative breast cancer researchers—Donald McDonnell, PhD, and Laura Esserman, MD, MBA—as this year’s recipients of their highest scientific honor, the Brinker Awards. Established by Komen in 1992, the awards recognize advances in the...
